U.S. Stock Summary: U.S. stocks edged lower on Tuesday, with the S&P 500 pulling back from record levels as financial specialists kept on pondering the instability over a Greek obligation arrangement and a delicate Ukraine ceasefire.
The S&P 500 lost 4.66 points, or 0.22 percent, to 2,092.33
The Dow Jones industrial average fell 48.74 points, or 0.27 percent, to 17,970.61.
Healthcare Sector Update: Biotechnology shares were relative pioneers, up on the day by around 1.8%. Driving the gathering were shares of (IBIO), up around 33.2% and shares of Cancer Genetics (CGIX) up around 14.6% on the day.
The biotechnology organizations are being forced by fence investments speculator Daniel Loeb to break itself separated.
Insights about some real gainers from healthcare segment, amid Wednesday’s exchange are depicted underneath:
iBio, Inc. (NYSE MKT:IBIO)’s shares skyrocketed 17.78% and led the share to close at $1.06, soon after a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies, declared the issuance of additional patents in the US and Europe covering novel plant viral vector-based protein expression technologies.
“These patents strengthen patent protection for commercial activities we are engaged in to improve the yield and functional properties of antibody products,” stated Robert Erwin, iBio’s president. “Some product candidates are intended to address opportunities in Brazil and we expect to commercialize those via our partner company, iBio do Brasil Biofarmaceutical Ltda., while others are predictable to be of interest to commercial partners in the U.S., Europe, and/or Japan.”
iBio, Inc. (NYSE MKT:IBIO), is developing a proprietary product, IBIO-CFB03, for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases using its iBioLaunch™ gene expression platform.
Shares of KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO), jumped nearly 15.56% and closed at $0.52. The stock has price to sale value of 4275.70, however, price to book value is 0.51. The mean recommendation of analysts for this stock is 2.00. (where 1=Buy, 5=Sale).
KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO), is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a focus on cancer.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), surged 15.13% to close at $14.69. as a developer of innovative RNA-based therapeutics, recently declared that administration is planned to take part in fireside chats at the following investor conferences in February. Chris Garabedian, Sarepta’s president and chief executive officer, will be the presenter.
2015 RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, February 24, at 11:30 a.m. EST.
The presentations will be webcast live on the investor relations section of the Sarepta Therapeutics website at www.sarepta.com and will be archived under the events and presentations section following each presentation for 90 days.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases.
Shares of the Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), gained 15.07% & closed at $3.36, soon after a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, recently declared the pricing of its formerly declared underwritten public offering. HART is offering 1,800,000 registered shares of its ordinary stock at a price to the public of $1.75 per share, and 695,857 registered shares of its Series B Convertible Preferred Stock at a price to the public of $8.75 per share, for predictable gross proceeds of about $9.2 million. At the option of the investor, the Series B is convertible into five shares of ordinary stock of the Company, and will vote with the ordinary stock on all matters on an as converted basis. The Series B has no preference to the ordinary shares in respect of dividends, voting, liquidation or otherwise. In connection with the offering, HART has also granted the underwriter a 30-day option to purchase up to an additional 270,000 shares of ordinary stock offered in the public offering to cover over-allotments, if any. HART intends to use the net proceeds from the offering primarily for research and development, counting funding pre-clinical and clinical trials regarding the HART-Trachea, business development, sales and marketing, capital expenditures, working capital and other general corporate purposes.
The offering is predictable to settle and close on February 18, 2015, subject to the satisfaction or waiver of customary closing conditions. National Securities Corporation, a wholly owned partner of National Holdings, Inc. (NHLD) is acting as sole book runner in the offering and Summer Street Research Partners is acting as co- manager for the offering.
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), makes regenerated organs for transplant. Our first product, the HART-Trachea, is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma.
